Gujarat Themis Biosyn Limited has informed the Exchange about Investor Presentation
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gujarat Themis Biosyn Limited (GTBL) has entered into an agreement to acquire Sanofi's Global Anti-TB and Anti-Infective product portfolio for approximately EUR 158 million. The acquisition includes 13 established global brands, marketing authorisations, dossiers, and inventory across 55+ countries, with FY2025 portfolio revenue of ~EUR 62 million. The deal is structured as an asset acquisition with no manufacturing facilities or employees transferred, funded by a mix of debt and equity. GTBL management expects this to significantly improve their margin profile through forward integration from fermentation to finished dosage forms, and considers the deal EPS accretive. The acquisition is subject to antitrust and FDI approvals.
This acquisition signals a major strategic expansion for GTBL into regulated markets with established brands, with management explicitly guiding toward margin improvement through vertical integration. The deal being EPS accretive and funded partly by debt suggests a growth-focused capital structure.